Dear authors, we greatly appreciated the systematic review and analysis of COVID-19 reported cases associated with the development of Takotsubo syndrome (TTS) [1]; however, we found two critical issues in reading your work.

Firstly, in the paper of Sala et al. [2], only a TTS pattern is described, rather than a reverse stress cardiomyopathy.

The 43-year-old female, with no previous cardiovascular disease, presented with oppressive chest pain; ST-segment elevation in leads V1, V2, and aVR with reciprocal ST depression in leads V4, V5, and V6 at ECG; elevation in cardiac and inflammatory biomarkers at lab exams; mild reduction of left ventricular function with hypokinesia of the mid and basal segments at transthoracic echocardiography and at dynamic 3D volume-rendering reconstruction of computer tomography; and absence of obstructive coronary disease at computed tomography angiography.

Although all these findings may be typical of both TTS and myocarditis, in order to clarify the diagnosis, Sala and colleagues referred the patient to perform both cardiac magnetic resonance and endomyocardial biopsy. After carrying out these investigations, according to the latest position statement of the European Society of Cardiology working group on myocardial and pericardial diseases [3], the final diagnosis was acute virus-negative lymphocytic myocarditis and not TTS complicated by myocarditis, as you reported. This patient should therefore be excluded from your systematic review.

In fact, despite the clinical presentation may be similar, TTS and myocarditis are two different entities (the former is a syndrome, and the latter is an inflammatory disease of the myocardium) with different diagnostic criteria, which allow differentiating one from the other.

In detail, to date, the diagnosis of TTS requires the fulfillment of all Mayo Clinic diagnostic criteria [4, 5], including the absence of myocarditis, so the diagnosis of the latter excludes that of TTS.

Secondly, although it may only be a typographical error, the paper by Taza et al. [6] described the development of TTS in a man of 52 years old and not of 82. Consequently, only 7 patients (instead of 8) were aged over 60 years old; moreover, the mean age of included patients may be slightly different from that reported in your systematic review.